Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy.

Jemmerson R

Open source

DOI
10.18632/oncoscience.667
Published
2026
Container
Oncoscience
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.18632/oncoscience.667,
  title = {Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy.},
  author = {Jemmerson R},
  year = {2026},
  journal = {Oncoscience},
  doi = {10.18632/oncoscience.667},
  url = {https://doi.org/10.18632/oncoscience.667}
}

RIS

TY  - JOUR
TI  - Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy.
AU  - Jemmerson R
PY  - 2026
JO  - Oncoscience
DO  - 10.18632/oncoscience.667
UR  - https://doi.org/10.18632/oncoscience.667
ER  - 

APA

R, J. (2026). Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy.. Oncoscience. https://doi.org/10.18632/oncoscience.667

Source records